Something small keeps showing up in the retatrutide threads that most side effect roundups never mention: people describing their own skin as suddenly touchy, like a sunburn that isn’t there. That detail matters because almost every retatrutide side effects list circulating right now is still quoting numbers from the 2023 Phase 2 trial. The Phase 3 program, TRIUMPH-1, reported its results in May 2026, and the picture shifted. The gastrointestinal effects still dominate the data, but the trial also surfaced something stranger: a skin sensation change nobody expected from a metabolic drug.
Jump to the FAQ for quick answers on how long this lasts, whether it’s dangerous, and what to tell your prescriber.
The gastrointestinal side effects, nausea, diarrhea, constipation, and vomiting, are the ones driving most of the Phase 3 numbers, and they follow the same pattern seen across the GLP-1 class. The genuine surprise is dysesthesia, a change in skin sensation that showed up in roughly one in five patients at the highest dose. None of this changes the fact that retatrutide remains investigational, unapproved, and not something to source outside of a clinical trial.
What Retatrutide Actually Is
Retatrutide is Eli Lilly’s investigational once weekly injectable, built to act on three receptors at once: GIP, GLP-1, and glucagon. It’s being studied for obesity, and as of mid-2026 it is not FDA approved. The pivotal Phase 3 trial, TRIUMPH-1, has reported its topline results, more readouts are expected through the rest of the year, and a regulatory submission is possible after that, though no approval date is set. If you’re curious about what that weight loss pace does to the face and skin specifically, what retatrutide’s weight loss pace does to skin and face is the deeper dive on that side of things; this article stays with what the trial reported about side effects across the board.
The Retatrutide Side Effects Phase 3 Actually Reported
TRIUMPH-1 enrolled 2,339 participants, and at the highest dose the gastrointestinal numbers look like this: nausea in 42.4 percent of participants, diarrhea in 32.0 percent, constipation in 26.1 percent, and vomiting in 25.3 percent. None of that is shocking if you’ve followed semaglutide or tirzepatide coverage. It’s the same family of side effects, and trial reporting says they cluster hardest during dose escalation rather than staying constant throughout. What’s driving people to tolerate that trade-off is the weight loss: 19.0 percent average at the 4mg dose, 25.9 percent at 9mg, and 28.3 percent at 12mg over 80 weeks, against 3.9 percent on placebo. Numbers like that are why retatrutide has an audience watching its approval path this closely, side effects included.
Dysesthesia, the One Nobody Saw Coming
Dysesthesia is the term the trial data uses for skin that becomes tingly, tender, or oddly sensitive to touch. It was reported by roughly 20.9 percent of participants at the highest dose in Phase 3 reporting, and trial documentation describes it as generally mild and something that tended to ease as treatment continued. If your skin sensation changes in any way, that’s a conversation for your prescriber or trial team, not something to diagnose off a forum thread. For a closer look at this specific symptom, our retatrutide skin and aesthetics guide covers it in depth.
Heart Rate: A Number for Your Clinician, Not You
Trials have also reported average heart rate increases of roughly 5 to 10 beats per minute. That’s not a number you’re meant to track and self-correct at home. It’s a monitoring item that belongs at your regular checkups, the kind of thing a clinician catches on a routine vitals check rather than something you’d notice on your own wrist.
What Actually Helps
Smaller, slower meals do more for the GI side of this than most people expect, especially on the days closest to a dose change. Bland, low-fat food strategies tend to be gentler when nausea flares. Steady hydration, with electrolytes if diarrhea or vomiting show up, matters more than people think, and fiber earns its keep on the constipation end. Protein intake deserves particular attention during any period of rapid weight loss; it’s part of what protects hair density during that stretch, which is why protecting your hair through rapid weight loss is worth reading before symptoms start rather than after. None of these steps replace calling your prescriber or trial team. They’re what you do while you wait to talk to them, not instead of talking to them.
Why Sourcing It Yourself Isn’t Worth the Risk
Retatrutide cannot be legitimately prescribed outside of a clinical trial right now. There is no pharmacy pathway and no approved compounding pathway, nothing legitimate outside of enrollment. The FDA has warned plainly against obtaining it from grey market or research chemical sources, and counterfeit products sold under its name may contain something else entirely, with no way for a buyer to verify what’s actually in the vial. Waiting for an actual approval, if one comes, is the only version of this that doesn’t involve gambling with an unregulated substance. For a sense of how this plays out with a drug that already made it through approval, the aesthetic side effect timeline on semaglutide is worth reading side by side with this one.
Normal vs. Call Your Prescriber
Normal in Trials
- Nausea and GI symptoms, especially early in dosing
- Mild skin sensitivity or tingling changes
- A modest heart rate increase noted at checkups
Call Your Prescriber Now
- Severe or persistent abdominal pain
- Symptoms suggesting pancreatitis or gallbladder trouble
- Signs of severe dehydration
- Vision changes
- A racing heart at rest
- Any skin sensation change that’s painful, spreading, or paired with a rash
Phase 3 Side Effects at a Glance
| Side Effect | Reported Rate at Highest Dose | What It Means for You |
|---|---|---|
| Nausea | 42.4% | Expected early in dosing, and usually settles as escalation continues |
| Diarrhea | 32.0% | Hydration and fiber help; report it if severe or persistent |
| Constipation | 26.1% | Fiber and fluids are the general wellness response; call if it doesn’t ease |
| Vomiting | 25.3% | Watch hydration closely; frequent vomiting belongs in the call-now column |
| Dysesthesia | 20.9% | Generally mild per trial reporting; any change is still worth flagging to your prescriber |
| Heart Rate Increase | 5 to 10 bpm | A checkup item for your clinician to monitor, not something to track and self-manage |
FAQ
Is retatrutide approved by the FDA yet?
No. As of mid-2026, retatrutide remains investigational. TRIUMPH-1 has reported its pivotal results, more Phase 3 readouts are expected through the year, and a regulatory submission is possible after that, though there’s no confirmed approval date yet.
What is dysesthesia, and does it mean something is wrong?
It’s a change in skin sensation, tingling, tenderness, or heightened sensitivity to touch, reported in about one in five participants at the highest trial dose. Trial reporting describes it as generally mild, but any new or changing skin sensation deserves a conversation with your prescriber or trial team rather than a guess.
Can I get retatrutide outside of a clinical trial?
Not legitimately. It has no approved prescription or compounding pathway yet, and the FDA has warned specifically against grey-market and research-chemical sources, since counterfeit versions may not contain what the label claims.
This article is for educational purposes only and is not a substitute for professional medical advice. Always follow your injector’s or surgeon’s specific aftercare instructions.
